CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 181 enrolled
Drug / intervention
chloroquine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02389374
NCT02389374Phase 4Completed

A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of Glucose-6-dehydrogenase Status in South-east Bangladesh

Menzies School of Health Research·interventional·Posted Mar 17, 2015·Updated Mar 13, 2024

In Brief

A Phase 4 clinical trial evaluating chloroquine, Artemether-lumefantrine combination, and 1 other intervention for Malaria. Completed, enrolled 181 participants.

Detailed Summary

This is a study assessing safety and efficacy of current national guidelines for the treatment of uncomplicated malaria in Bangladesh as well as to assess the G6PD status among the enrolled patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
Countries--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 17, 2015
Enrollment StartAug 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.3 years ago

Interventions

chloroquinedrug

standard dose

Artemether-lumefantrine combinationdrug

standard dose

Primaquinedrug

single dose

Primaquinedrug

14 days